Thus, these results indicate that the LRIG2-induced anti-cancer activities on endometrial carcinoma involve PI3K/AKT and EGFR activation followed by the regulation of MCL-1, BAK, BAX, and p21 expression. This evidence concerns the gene LRIG2 and endometrial carcinoma.